Clinical trials: Influenza Vaccines
Influenza, Influenza, Human
Revaccination With Influenza Vaccine GSK1247446A
The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.
- Trial name
- NCT00545025
- Testing
- Influenza Vaccine GSK1247446A, Fluarix™
- Where
- Belgium
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Children younger than 5 years of age are at high risk for severe influenza disease (flu) and hospitalization due to flu. Scientists are in the process of re-evaluating the dosing initially based on whole virus vaccines to improve…
- Trial name
- NCT00778895
- Testing
- GSK Biologicals' influenza vaccine GSK1557482A, Vaxigrip
- Where
- 18 sites in Canada
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.
- Trial name
- NCT04439695
- Testing
- Low dose, Intermediate dose, High dose
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Influenza
Study to Evaluate an Influenza Vaccine Candidate
The purpose of this study is to evaluate the immune response and safety of influenza vaccine candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
- Trial name
- NCT00321373
- Testing
- Candidate Influenza Vaccine GSK1247446A - 2 different formulations, FluarixTM
- Where
- 17 sites in Finland, Greece
- Volunteers
- 1,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
This partially randomized, multi-center parallel-group study will evaluate the safety, pharmacokinetics and the effect on viral load and viral shedding of Tamiflu (Oseltamivir) in patients with influenza.
- Trial name
- NCT01050257
- Testing
- Oseltamivir IV, Oseltamivir Oral
- Where
- 96 sites in United States, Denmark and 7 more
- Volunteers
- 118 people
- Sponsor
- Hoffmann-La Roche
Influenza
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
The aim of the study was to assess the immunogenicity and safety of Fluzone Quadrivalent influenza vaccine Southern Hemisphere (SH) 2015 formulation in participants aged 18 to 60 years as well as in participants 61 years or…
- Trial name
- NCT03546192
- Testing
- Fluzone Quadrivalent Influenza Vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human, Flu, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.
- Conditions
- Influenza, Human, Flu, Human, Flu, Avian, Influenza
- Trial name
- NCT02107807
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 17 sites in Australia, Germany and 1 more
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of 2012-2013 trivalent seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy older…
- Trial name
- NCT01736709
- Testing
- 2012-2013 trivalent seasonal influenza vaccine
- Where
- China
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Influenza A
Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI
The goal of this prospective, digital randomized controlled trial is to evaluate the effectiveness of a predictive ILI detection algorithm and associated alerts during influenza season for adults living in the contigent United…
- Conditions
- Influenza, Influenza A, Influenza B, COVID-19
- Trial name
- NCT06229444
- Testing
- ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content
- Where
- United States
- Volunteers
- 17,043 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
The aim of the study was to describe the safety and immunogenicity of the 2016-2017 formulations of Fluzone Quadrivalent vaccine in children 3 to < 9 years of age and in adults 18 to < 65 years or age, and of the 2016-2017…
- Trial name
- NCT02908269
- Testing
- Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Infection
Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in healthy Japanese adults
- Trial name
- NCT02313155
- Testing
- Subcutaneous injection of TAK-850, Intramuscular injection of TAK-850
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, COVID-19 (Coronavirus Disease 2019)
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older.
- Trial name
- NCT06821061
- Testing
- Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine
- Where
- 31 sites in United States
- Volunteers
- 2,650 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Upper Respiratory Infection
Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults
The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continuing care facilities.
- Trial name
- NCT00259831
- Testing
- CVT-E002 (Cold-FX); a natural health product
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Adverse Drug Reactions
A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women
This was a retrospective cohort study of pregnant women who had received the AdimFlu-S (A/H1N1) influenza vaccine during gestation period. Eligibility into the study was confirmed by chart review.
- Trial name
- NCT01354730
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to < 18 years of age who are at risk of complications of influenza disease due to underlying diseases.
- Trial name
- NCT01998477
- Testing
- TIVc, TIV
- Where
- 16 sites in Italy, Spain
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infectious Diseases, Healthy Subjects
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
This single-center, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel® = tested product) on the incidence of…
- Conditions
- Infectious Diseases, Healthy Subjects, Respiratory Tract Infections, Sore Throat
- Trial name
- NCT01033799
- Testing
- Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®), Non fermented dairy product (control)
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.